OBJECTIVES The purpose of this study was to assess the relationship between biomarkers of renin-angiotensinaldosterone system (RAAS) activation and decongestion strategies, worsening renal function, and clinical outcomes.
A ctivation of the renin-angiotensinaldosterone system (RAAS) plays a fundamental role in the pathophysiology of heart failure (1, 2) . Various strategies for decongestion in acute heart failure (AHF) patients, such as loop diuretic therapy or ultrafiltration (UF), have been posited to lead to greater or lesser degrees of RAAS activation (3, 4) . For instance, reviews of loop diuretic agents cite the potential of these agents, especially at high doses, to cause RAAS activation (5, 6) , a potential mechanism of the observational link between diuretic dosing and adverse outcomes (7) (8) (9) . Data supporting this concept, however, generally predate current pharmacotherapy for heart failure (10, 11) . Additionally, RAAS activation is frequently cited as a primary driver of worsening renal function (WRF) in AHF patients (i.e., the cardiorenal syndrome) (12) . Contemporary data to support this statement are also limited. Finally, the association between the degree of RAAS activation and outcomes after AHF hospitalization in patients treated with contemporary heart failure therapy is unknown.
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Of note, the 56 patients who were excluded tended to be nonwhite and had lower EF and better renal function than the study cohort. At baseline, the median PRA in the study population was 5 ng/ml/h, and the median aldosterone level was 210 pg/ml. Patient characteristics on the basis of the median split of baseline RAAS biomarkers are displayed in Table 1 .
Overall, patients with greater baseline RAAS activation had more implantable cardioverter-defibrillator (ICD) use, lower blood pressure, lower serum sodium, and higher blood urea nitrogen (BUN) levels than those with lower baseline RAAS activation. In addition, those with higher baseline RAAS levels tended to have a higher frequency of aldosterone antagonist therapy and higher baseline doses of furosemide. Patients with higher PRA levels were more often white, had New York Heart Association functional class IV symptoms, and had lower Nterminal pro-B-type natriuretic peptide (NT-proBNP) levels at baseline. Those with higher baseline aldosterone levels tended to have lower LVEF, were less likely to receive ACE-I/ARB, and had higher baseline creatinine levels.
Patients receiving ACE-I/ARB therapy had similar baseline PRA and lower baseline aldosterone levels than those not receiving these agents (median PRA:
4.4 ng/ml/h vs. 5.4 ng/ml/h, respectively; p ¼ 0.18; and median aldosterone: 168 pg/ml vs. 283 pg/ml, respectively; p < 0.0001) (Online Table 2 ). Patients receiving aldosterone antagonists had significantly higher PRA and aldosterone levels compared with those not receiving aldosterone antagonists (median: 10.0 ng/ml/h vs. 3.2 ng/ml/h and 327 pg/ml vs.
175 pg/ml, respectively; both: p < 0.001). Between randomization and discharge, ACE-I/ARB therapy was discontinued for 10.9% of patients and initiated for 8% of patients. Also, aldosterone therapy was discontinued for 6.1% of patients and initiated for 9.2% of patients between randomization and discharge.
BIOMARKER CHANGE BY DECONGESTION STRATEGY. (Table 3) . Specifically, p Values correspond to the treatment effect in linear regression models for 72-or 96-h RAAS, adjusted for baseline RAAS, use of baseline ACE-I/ARB, and use of baseline aldosterone antagonist where a log base 2 transformation was applied to both the baseline and the follow-up RAAS measure.
CARRESS ¼ Cardiorenal Rescue Study in Acute Decompensated Heart Failure; DOSE ¼ Diuretic Optimization Strategies in Acute Heart Failure; other abbreviations as in Table 1 .
a 10-unit increase in PRA was associated with an 80% increase in WRF, and a 100-U increase in aldosterone was associated with a 13% increase in WRF.
Over a follow-up period of up to 127 days, 134 patients (31.4%) died or were rehospitalized for HF.
There was a total of 52 deaths (12.2%). were associated with lower rates of death or HF rehospitalization than quartile 4, but these differences were not statistically significant (Online Table 5 ). The change in RAAS biomarkers from baseline to 72 h or 96 h was not associated with outcomes (both: p > 0.5).
DISCUSSION

Data from both the DOSE-AHF and CARRESS-HF
populations provide a unique opportunity to examine RAAS activation across a spectrum of patients with AHF. Additionally, the fact that patients were randomly assigned to specific decongestion strategies eliminates a major potential confounder of observational data, in that sicker patients tended to be treated with more intensive therapy. We found that patients with baseline RAAS biomarker levels greater than the median had features of more severe disease, including lower blood pressure and serum sodium, higher BUN levels, and higher baseline outpatient loop diuretic doses. Contrary to our hypothesis and previous report findings, we found no evidence that higher doses of loop diuretics led to greater activation of RAAS from baseline to 72 h. were measured within hours of therapy (10) or in the outpatient setting (11, 16) . Thus, our findings in contrast to those of earlier studies may be partly related to the timing of sample acquisition. Our findings may also be different than those expected from previous experience, in part because the DOSE and CARRESS studies were designed to identify patients with evidence of excess circulating volume, and therapy was adjusted specifically to return patients to euvolemia. Notably, a recent small study of UF versus diuretic therapy in 30 AHF patients also demonstrated that fairly high-dose diuretics did not stimulate aldosterone levels (20) . Therefore, these data should allay concerns for adverse effects on RAAS activation with higher-dose diuretics in volume-overloaded AHF patients receiving contemporary RAAS inhibitors. Interestingly, high-dose loop diuretics were not associated with more RAAS *HR for change in RAAS activation measure $ median versus < median (PRA median ¼ 1.058 ng/ml/h; aldosterone median ¼ À0.95 pg/ml) from proportional hazards regression model adjusted for trial, baseline RAAS activation, and baseline ACE-I/ARB and aldosterone antagonist use. †OR for 10-U increase in PRA and 100-U increase in aldosterone. Proportional hazards regression models were adjusted for trial, baseline RAAS activation, and ACE-I/ARB and aldosterone antagonist use.
WRF ¼ worsening renal function; other abbreviations as in Table 1 .
FIGURE 4 Scatterplots of Net Fluid Loss and Change in Biomarkers
Scatterplots of net fluid loss and change in biomarkers of RAAS activation from baseline to 72 h (DOSE-AHF study) or to 96 h (CARRESS-HF study).
PRA ¼ plasma renin activity; other abbreviations as in Figure 1 .
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RAAS Activation and Decongestion *Hazard ratio (HR) for RAAS activation measure $ median versus < median (PRA median ¼ 5 ng/ml/h; aldosterone median ¼ 210 pg/ml) from proportional hazards regression model adjusted for trial, and baseline ACE-I/ARB and aldosterone antagonist use. †Hazard ratio for doubling of RAAS activation measurement from proportional hazards regression model adjusted for trial and baseline ACE-I/ARB and aldosterone antagonist use. ‡Proportional hazards regression models for change in RAAS activation from baseline to 72 h or 96 h, adjusted for trial, baseline RAAS activation, and ACE-I/ARB and aldosterone antagonist use. Table 2 .
Abbreviations as in
aldosterone with UF was À9 pg/ml, but the standard deviation was nearly 500 pg/ml. Thus, some patients are outliers with a marked neurohormonal response to different decongestion therapies. Future studies are needed to identify the characteristics and outcomes of these patient subgroups. Furthermore, although there was no differential increase in RAAS activation between high-and low-dose diuretics, the PRA increase with either approach was fairly high (median increase: 1.58 ng/ml/h with low-dose and 1.03 ng/ml/h with high-dose). Given the high morbidity and mortality rates in both arms in DOSE, the possible implications of this RAAS change requires further study. Second, the absolute degree of RAAS activation and at 72 h or 96 h, we were unable to explore the trajectory of biomarkers with further granularity (e.g., peak, nadir, and rate of change over several time points). The dynamic nature of these biomarkers may have limited our ability to observe an association with outcomes due to bias related to the timing of sample acquisition. Importantly, these findings should not be interpreted to indicate that elevation in RAAS biomarkers at baseline is benign, since the event rate was quite high in these patients (i.e., >30% were rehospitalized or dead within 60 days). We provide contemporary evidence that is in contrast to previous data and hypotheses regarding RAAS activation, AHF therapy, and post-discharge clinical outcomes. High-dose loop diuretics did not result in greater RAAS activation than low-dose diuretics.
However, UF resulted in greater PRA increase than stepped pharmacologic care. An increase in RAAS biomarkers from baseline was associated with WRF. PRA and aldosterone were not significantly associated with short-term post-discharge outcomes in this AHF cohort.
